Manuj Agarwal, Radiation Oncologist at MidLantic Urology, shared on LinkedIn:
“This message from a prostate cancer patient sparked a career shift.
At the time, I was increasingly disillusioned with academic medicine and burned out. I wanted more room to address the person’s health beyond the cancer itself.
This man had biopsy-confirmed prostate cancer and was on active surveillance. He wanted to know what he could do while we monitored his cancer. He asked questions, researched and acted on our conversations. Then he sent me this message.
What stayed with me was his sense of agency. He could participate in his care between appointments, rather than simply wait for the next result.
Four years later, he remains under my care on active surveillance. His latest MRI was negative, and no cancer was found on his repeat biopsy.
His experience helped clarify what I wanted to build: a practice where helping patients understand and participate in their health was central to the work.
Academic medicine had given me valuable training. Its structure was leaving too little room for the direction I wanted to take.
Blue Wellth grew from that tension – and from patients like him who showed me why that direction mattered.
‘As a result of the generous advice from you and your resident + a bit of additional my own research, my PSA went from a steady increase peaking at 4.59 ng/mL to 3.575 ng/mL and my PI-RADS 4 lesion is now PI-RADS 2 in less than 8 months.
Glad to share details of my regimen if interested.”
You can also read: PSMA PET and MRI-Guided Prostate SABR With Focal Boost Shows Promising Two-Year Outcomes in ARGOS-CLIMBER Trial
